Prevention Of Multi-drug Resistant Tuberculosis In A High Prevalence Setting: ‘Connecting The DOTS’ In Vietnam
Funder
National Health and Medical Research Council
Funding Amount
$3,382,020.00
Summary
The close contacts of people with multi-drug resistant tuberculosis (MDR-TB) have a high risk of developing the disease. The V-QUIN MDR-TB Trial will evaluate the effectiveness of an oral antibiotic (levofloxacin) in preventing drug resistant TB among infected household contacts of TB patients. Household contacts from 10 Provinces in Vietnam will be randomly allocated to receive six-months of either levofloxacin or a placebo, and then followed for two years to see if they develop tuberculosis.
Impact Of An Ivermectin Mass Drug Administration Program Against Endemic Scabies And Strongyloidiasis
Funder
National Health and Medical Research Council
Funding Amount
$1,289,786.00
Summary
Overseas studies suggest sustainable and long term benefits can be obtained through the use of ivermectin in mass drug administration programs to control parasitic infections. Our study will be a critical first step in establishing if such a program can be successful in a remote Indigenous community setting, where the disease burden from scabies and strongyloidiasis (threadworm infections) is very high.
Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less